List of Excipients in Branded Drug HEPATAMINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	HEPATAMINE	isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alani	0264-9371	SODIUM BISULFITE
B Braun Medical Inc	HEPATAMINE	isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alani	0264-9371	WATER

HEPATAMINE Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

HEPATAMINE is an 8% amino acid injection for parenteral nutrition in patients with hepatic disease. Its commercial opportunity is driven less by composition-of-matter exclusivity and more by formulation quality, container technology, supply reliability, compatibility data, and differentiated parenteral-nutrition positioning. The most defensible strategy is a preservative-free, ready-to-use amino acid solution with tightly controlled pH, low particulate burden, robust container-closure performance, and validated admixture stability.

What is HEPATAMINE and how is it used?

HEPATAMINE is a sterile intravenous amino acid formulation intended to provide nitrogen and amino acids to patients requiring parenteral nutrition, particularly patients with impaired hepatic function. The product contains a balanced mixture of crystalline L-amino acids, with the profile designed for patients with hepatic disease and altered amino-acid metabolism.[1]

The formulation is administered intravenously, generally as part of a broader parenteral-nutrition regimen that can include dextrose, lipid emulsions, electrolytes, vitamins, trace elements, and other clinically required components. HEPATAMINE is not a complete parenteral-nutrition product by itself.

HEPATAMINE product profile

Attribute	Product profile
Product	HEPATAMINE
Dosage form	Sterile intravenous injection
Strength	8% amino acid solution
Therapeutic category	Parenteral nutrition and amino-acid replacement
Primary clinical setting	Hospital and institutional care
Patient population	Patients with hepatic disease requiring parenteral nutrition
Active components	Crystalline L-amino acids
Primary formulation risk	Amino-acid degradation, precipitation, oxidation, particulates, and container interaction
Commercial substitutes	General amino acid injections, hepatic-specific amino acid products, compounded parenteral nutrition, and oral or enteral nutrition when clinically appropriate

The product label describes the formulation, preparation, administration, warnings, and compatibility requirements that govern its use.[1]

What excipients are used in HEPATAMINE?

HEPATAMINE is an aqueous amino acid injection. Its excipient strategy is intentionally narrow because intravenous nutrition products have limited tolerance for preservatives and unnecessary formulation components.

The principal non-active components are water for injection and pH-adjusting acid, identified in the product labeling. The amino acids themselves are the active pharmaceutical ingredients. Commercial development should distinguish those active ingredients from excipients because the regulatory and intellectual-property analysis differs for each category.[1]

Functional role of HEPATAMINE excipients

Formulation component	Functional purpose	Commercial significance
Water for injection	Primary solvent and injectable vehicle	Requires control of endotoxins, bioburden, conductivity, and particulate matter
Acetic acid or other labeled pH adjuster	Controls solution pH and supports amino-acid stability	Influences precipitation risk, tolerability, and admixture compatibility
Container-closure system	Protects the sterile solution from oxygen, light, and extractables	Creates opportunities for differentiation through bags, ports, overwraps, and oxygen-barrier materials
Amino-acid blend	Provides the nutritional and therapeutic activity	Determines the product's hepatic-nutrition positioning and labeling scope

A preservative-free presentation is generally preferable for a large-volume intravenous nutrition product. Preservatives can create safety and compatibility concerns, particularly in neonates, critically ill patients, and patients receiving multiple simultaneous infusions. A developer should avoid adding an antimicrobial preservative unless the intended presentation and regulatory justification clearly support it.

How should an excipient strategy for HEPATAMINE be designed?

The strongest formulation strategy is to optimize the product around stability, usability, and admixture performance rather than adding novel excipients.

pH control

Amino-acid solutions are sensitive to pH. Excessive acidity can affect infusion-site tolerability and compatibility with other parenteral-nutrition components. A higher pH can increase the risk of precipitation or degradation for selected amino acids and may affect trace-element compatibility.

The target pH should be established through a design-of-experiments program covering:

• Amino-acid concentration
• Temperature
• Oxygen exposure
• Light exposure
• Dextrose co-administration
• Electrolyte concentration
• Calcium and phosphate loading
• Trace-element combinations
• Storage duration after admixture

The pH-adjusting agent should be selected based on its regulatory acceptability, ionic contribution, buffer capacity, and impact on long-term stability.

Oxygen and oxidation control

Tryptophan, methionine, cysteine if present in an admixture, and other components can be vulnerable to oxidative degradation. Oxygen exposure can increase discoloration and impurity formation. A commercial formulation should evaluate:

• Nitrogen purging during filling
• Low-oxygen headspace
• Oxygen-barrier overwraps
• Low-oxygen container materials
• Light-protective packaging
• Container-closure integrity
• Shipping exposure under elevated temperature

The preferred design is usually a low-excipient formulation combined with a better oxygen-control system. This approach can reduce extractables and simplify the inactive-ingredient profile.

Particulate and precipitation control

Parenteral-nutrition products have strict requirements for visible and subvisible particulates. The formulation should be assessed after storage, transport, cold exposure, warming, and admixture with dextrose, lipids, electrolytes, vitamins, and trace elements.

Calcium-phosphate precipitation is a major risk in parenteral nutrition, although the risk depends on the final admixture rather than the amino-acid solution alone. The product should include validated compatibility instructions and clear restrictions on mixing order, storage temperature, and maximum use time. FDA guidance places significant emphasis on pharmaceutical quality and lifecycle controls for injectable products.[2]

What formulation patents could protect a HEPATAMINE follow-on product?

A basic amino-acid injection containing conventional amino acids and water for injection is unlikely to provide a strong composition-of-matter patent position. The commercial value is more likely to reside in formulation, packaging, manufacturing, and use claims.

Potential patentable features include:

1. A specific amino-acid ratio optimized for a defined hepatic population.
2. A low-impurity formulation with defined degradation limits.
3. A pH range that improves stability while preserving admixture compatibility.
4. A low-oxygen container-closure system.
5. A ready-to-use dual-chamber or multi-chamber presentation.
6. A premixed hepatic parenteral-nutrition formulation with specified dextrose, lipid, electrolyte, vitamin, or trace-element content.
7. A manufacturing process that reduces oxidation or particulate formation.
8. A method for improving nitrogen delivery in patients with hepatic encephalopathy or severe liver dysfunction.
9. A stability profile supporting extended refrigerated or room-temperature storage.
10. A compatibility protocol supporting longer post-admixture use periods.

Patent strength by claim type

Claim category	Expected strength	Commercial value
Conventional amino-acid composition	Low	Low
Narrow amino-acid ratio with clinical evidence	Moderate	Moderate to high
pH and stability range	Moderate if unexpected results are shown	Moderate
Container and oxygen-control system	Moderate	Moderate
Multichamber or ready-to-use system	Moderate to strong	High
Manufacturing process	Moderate	Moderate
Method-of-use claim	Variable	Moderate
Broad hepatic-nutrition indication	Low to moderate	Dependent on clinical evidence

Patent protection will be stronger where the formulation produces measurable, unexpected results, such as lower impurity growth, fewer particulates, longer admixture stability, or improved clinical outcomes.

What is the Orange Book status of HEPATAMINE?

HEPATAMINE's primary commercial protection is not expected to depend on an active patent estate. The product is an older sterile injectable nutritional formulation, and the relevant commercial barriers are likely to be regulatory approval, manufacturing capability, hospital contracting, supply continuity, and clinical familiarity rather than extended exclusivity.

The FDA Orange Book should be checked for the current reference-listed-drug designation, patent listings, and exclusivity information before filing or licensing decisions are made.[3] A product that has no active Orange Book patents can still create substantial market-entry difficulty because sterile injectable manufacturing requires validated aseptic processing, container-closure qualification, extractables and leachables work, stability data, and reliable commercial-scale supply.

When does HEPATAMINE lose exclusivity?

For an older amino-acid injection, any original regulatory exclusivity is likely to have expired. The relevant question is whether a current patent, approved labeling restriction, or market-specific contract creates a practical barrier to entry. The absence of a listed patent would generally support an ANDA-based competitive strategy if the proposed product can meet the applicable pharmaceutical-equivalence and bioequivalence requirements.

A follow-on applicant should evaluate:

• Orange Book listing status
• FDA approval history
• Reference-listed-drug availability
• Inactive-ingredient differences
• Sterility and endotoxin controls
• Labeling differences
• Product-specific bioequivalence expectations
• Drug-shortage history
• Current manufacturing capacity

Can a generic manufacturer challenge HEPATAMINE?

A generic manufacturer could potentially pursue an abbreviated application if the product qualifies as an ANDA reference product and the proposed formulation meets FDA requirements for pharmaceutical equivalence, labeling, quality, and performance.

A Paragraph IV certification is relevant only if the reference product has an applicable listed patent. If no enforceable patent is listed, the applicant would not need to build its strategy around a Paragraph IV challenge. The key risk would instead be FDA review of the formulation, manufacturing process, container system, and proposed differences in inactive ingredients.

For an injectable product, the regulatory assessment may focus heavily on:

• Same strength and route of administration
• Same active amino-acid components
• Sterility assurance
• Endotoxin compliance
• Particulate control
• pH and osmolality
• Container-closure integrity
• Stability
• Compatibility with the approved administration method
• Absence of clinically meaningful excipient differences

FDA's ANDA and pharmaceutical-equivalence frameworks govern the pathway for generic versions of approved drug products.[4]

What commercial opportunities exist for HEPATAMINE alternatives?

The most attractive opportunities are differentiated presentations and supply-chain improvements.

Ready-to-use parenteral nutrition

Hospitals face labor, contamination, and error risks when pharmacy staff compound parenteral nutrition. A ready-to-use hepatic amino-acid product could reduce compounding steps and support standardized protocols.

Commercial designs include:

• Single-use bags
• Pharmacy-ready bottles
• Dual-chamber systems
• Standardized amino-acid and dextrose combinations
• Hospital-specific formulation strengths
• Barcoded products compatible with automated compounding systems

The product should not be marketed as a complete nutritional regimen unless the formulation and labeling support that claim.

Improved container technology

A lower-oxygen, light-protective container may support longer shelf life and reduce discoloration or impurity growth. Multilayer polymer bags, improved ports, and oxygen-barrier overwraps can create meaningful differentiation without changing the amino-acid blend.

Packaging claims are most commercially useful when they produce measurable benefits:

• Longer expiration dating
• Lower oxygen ingress
• Reduced adsorption
• Fewer extractables
• Better shipping stability
• Improved port integrity

Hepatic and renal nutrition platforms

A company with a broader parenteral-nutrition portfolio could position HEPATAMINE-type products alongside renal, pediatric, trauma, and standard amino-acid injections. The commercial value increases when the product is part of a hospital formulary strategy rather than sold as a single niche product.

Potential platform products include:

Product concept	Target setting	Differentiation
Hepatic amino-acid injection	Advanced liver disease	Disease-specific amino-acid profile
Renal amino-acid injection	Acute or chronic renal impairment	Reduced or modified electrolyte and amino-acid burden
Pediatric formulation	Neonatal and pediatric nutrition	Lower volume, tighter impurity controls, age-specific labeling
Ready-to-use hepatic nutrition bag	Intensive care and hospital pharmacy	Reduced compounding workload
Extended-stability admixture	Central pharmacy and home infusion	Longer use period after preparation
Low-volume high-concentration product	Fluid-restricted patients	More nitrogen delivery per infused volume

What manufacturing and intellectual-property barriers affect market entry?

Sterile manufacturing is the primary operational barrier. The amino acids are generally available as commodity pharmaceutical ingredients, but the final product requires controlled aseptic production and validated packaging.

Key manufacturing controls include:

• Qualified pharmaceutical-grade amino acids
• Control of bioburden before sterilization or sterile filtration
• Aseptic filling validation
• Filter compatibility
• Container-closure integrity
• Particulate inspection
• Endotoxin testing
• Stability-indicating analytical methods
• Control of amino-acid impurities
• Management of oxygen and light exposure
• Shipping qualification

A developer may obtain a stronger competitive position through manufacturing know-how than through broad patents. Process parameters, supplier qualification, impurity-control methods, and filling conditions can be protected as trade secrets where patent disclosure would provide limited value.

Which companies are positioned to compete with HEPATAMINE?

Competition is likely to come from established parenteral-nutrition suppliers rather than conventional small-molecule generic companies. Relevant competitive capabilities include sterile injectable manufacturing, hospital distribution, nutrition-support sales, and pharmacy-compounding relationships.

The competitive field may include:

• Fresenius Kabi
• Baxter
• B. Braun
• Hikma
• Pfizer and Hospira-related injectable channels
• Regional sterile-injectable manufacturers
• Contract manufacturers with parenteral-nutrition capabilities

The strongest competitors are those with existing hospital contracts, established quality systems, and the ability to supply amino-acid injections consistently. A new entrant with a technically equivalent product may still face lengthy formulary conversion cycles and price pressure.

What revenue exposure and launch scenarios exist?

HEPATAMINE is a niche institutional product. Revenue potential depends on hospital volume, contract access, product availability, and the ability to win pharmacy and nutrition-support committee adoption.

Launch scenarios

Scenario	Product strategy	Market result
Commodity generic	Same basic formulation and container	Price-driven competition
Supply-reliability entrant	Equivalent formulation with dependable availability	Gains during shortages or allocation periods
Packaging differentiator	Better oxygen control and handling	Moderate premium potential
Ready-to-use product	Reduced compounding burden	Higher value per unit, stronger hospital case
Clinical differentiation	New amino-acid ratio supported by evidence	Potential premium and narrower competition
Portfolio platform	Hepatic product paired with renal, pediatric, and standard products	Greater contracting leverage

Revenue exposure is more sensitive to supply interruptions than to consumer demand. Hospitals may tolerate a modest price premium for a reliable product if the alternative is compounding, substitution, or delayed treatment. The premium declines when multiple suppliers offer interchangeable amino-acid injections.

How strong is the HEPATAMINE patent estate?

The patent estate is likely weak as a barrier to a conventional generic formulation. The stronger protection opportunities are formulation-specific and operational.

A commercial diligence review should classify identified rights into four groups:

1. Active composition or ratio patents.
2. Formulation and stability patents.
3. Packaging and container patents.
4. Manufacturing and admixture-method patents.

The most valuable rights would cover a clinically relevant hepatic amino-acid profile combined with stability or handling advantages. Broad claims covering common amino acids in water for injection are more vulnerable to invalidity and design-around arguments.

Key Takeaways

• HEPATAMINE is an 8% intravenous amino-acid product for parenteral nutrition in hepatic disease.
• Its excipient system is deliberately limited, centered on water for injection and pH adjustment.
• The best formulation opportunity is a preservative-free product with improved oxygen control, particulate performance, and admixture stability.
• Conventional composition patents are unlikely to create a durable barrier.
• Packaging, ready-to-use presentations, and manufacturing processes offer stronger commercial differentiation.
• A generic entry strategy would likely focus on ANDA requirements, not a Paragraph IV litigation campaign, unless current Orange Book patents are listed.
• The principal barriers are sterile manufacturing, quality systems, hospital contracting, supply reliability, and clinical familiarity.
• The highest-value opportunity is a hepatic parenteral-nutrition platform that includes differentiated packaging or ready-to-use admixture formats.

Frequently Asked Questions

Can HEPATAMINE be reformulated as a premixed parenteral-nutrition bag?

Yes, but the developer would need to establish compatibility and stability for the complete admixture, including dextrose, electrolytes, lipids, vitamins, trace elements, and the intended container system. The premixed product would require a distinct quality and labeling strategy.

Are preservatives appropriate in HEPATAMINE?

A preservative-free design is generally preferable for an intravenous nutrition product. Any preservative would require a specific safety, compatibility, and regulatory justification and could limit use in vulnerable patient populations.

Could a new HEPATAMINE formulation obtain orphan-drug protection?

Possibly only if it targets a qualifying rare disease or rare subpopulation and satisfies FDA orphan-drug criteria. A general hepatic-nutrition indication would not ordinarily qualify merely because the product treats a specialized hospital population.[5]

Is a HEPATAMINE biosimilar possible?

No. HEPATAMINE is a chemically defined amino-acid drug product, not a biologic. A competing product would be evaluated through the generic-drug or applicable new-drug pathway rather than the biosimilar pathway.

What is the most defensible commercial claim for a HEPATAMINE follow-on?

The strongest claim is likely to be improved usability or stability, such as reduced oxygen exposure, extended admixture stability, lower particulate formation, or a ready-to-use presentation. These claims require comparative analytical and stability evidence.

References

1. U.S. Food and Drug Administration. (n.d.). HEPATAMINE (8% amino acid injection) prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2004). Guidance for industry: Sterile drug products produced by aseptic processing - Current good manufacturing practice. https://www.fda.gov

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2022). ANDA submissions - Content and format. https://www.fda.gov

5. U.S. Food and Drug Administration. (2023). Orphan drug designation: Guidance for industry. https://www.fda.gov